Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.48 |
| ▸ | DDB1 | Q16531 | 15/20 | 0.48 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25091816 | 0.78 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25819002 | 0.78 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL20812175 | 0.74 | CRBN (0.51) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25935882 | 0.72 | CRBN (0.44) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25810467 | 0.72 | CRBN (0.58) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL19240421 | 0.71 | TSHR (0.36) | ALDH1A1TSHR | |
| SCHEMBL24414118 | 0.70 | CRBN (0.52) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL25810465 | 0.70 | CRBN (0.57) | CRBNDDB1IKZF3ALDH1A1CHRM2 | |
| SCHEMBL10141577 | 0.70 | NLRP3 (0.31) | — | |
| SCHEMBL20812622 | 0.69 | CRBN (0.47) | CRBNDDB1IKZF3ALDH1A1CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | UPPTHERA, INC. (KR) | 2024-02-27 | — | — | US | disclosed |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-08-03 | — | — | US | disclosed |
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | UPPTHERA, INC. (KR) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219966-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885IKZF3 1904/4885 |
| US-20230242541-A1 | NOVEL PLK1 DEGRADATION INDUCING COMPOUND | PLK1, BUB1B, BUB1 | CRBN 2136/4885DDB1 132/4885IKZF3 1904/4885 |
| US-11912710-B2 | Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers | PLK1, BUB1B, BUB1 | CRBN 2496/4885DDB1 77/4885IKZF3 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.